System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42825510 DOI: 10.1080/1061186X.2026.2742499

Hydrogel Stabilised Nanostructured Lipid Carrier Fortified Triamcinolone Acetonide for the Management of Atopic Dermatitis.

J Drug Target

Authors: Gajanan S Shinde, Himanshu Paliwal, Anil Kumar Singh, Anilkumar J Shinde, Sachin S Mali, Indrayani R Mohite, Asha S Jadhav, Vijay R Chidrawar, Sudarshan Singh, Bhupendra G Prajapati

Affiliations

  • Department of Pharmaceutics, Bharati Vidyapeeth College of Pharmacy, Kolhapur 416013, Maharashtra, India.
  • Marwadi University Research Center, Faculty of Pharmacy, Marwadi University, Rajkot, Gujarat, 360003, India.
  • Department of Pharmaceutics, United College of Pharmacy, Prayagraj 211010, Uttar Pradesh, India.
  • Department of Pharmacology, School of Pharmacy and Technology Management, SVKM's NarseeMonjee Institute of Management Studies (NMIMS), Deemed-to-university, Green Industrial Park, TSIIC, Jadcherla, Hyderabad 509301, India.
  • SNJB's Shriman Sureshdada Jain College of Pharmacy, Neminagar, Chandwad, Nashik, Maharashtra 423101, India; Affiliated to Savitribai, Phule Pune University (SPPU, Pune), Pune, Maharashtra, 422213, India.
  • Department of Pharmaceutics, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, Waghodia, Vadodara, Gujarat, 391760, India.

Abstract

Atopic dermatitis (AD) is a long-term skin disease that causes redness, itching, and a loss of skin barrier function, which sometime shows significant effect on a person's quality of life. In this study nanostructured lipid carrier (NLCs)-based hydrogel was fabricated for the topical delivery of triamcinolone acetonide (TA) with enhance therapeutic efficacy for the management of AD. TA-loaded NLCs were developed using high pressure homogenizer and characterized. The optimized NLCs composition showed a particle size of 92.06 nm, PDI of 0.324, ZP of -28.81 mV, and entrapment efficiency of 85.17%, suggesting good stability and drug incorporation. Ex vivo skin permeation studies of TA-NLCs hydrogel demonstrated sustained drug permeation of 79.86% at 8 h, significantly higher, comparedto pure drug incorporated hydrogel (p < 0.05). Skin irritation studies verified the safety of the formulation with no significant signs of edema and erythema. The anti-inflammatory effect was assessed using a carrageenan-induced rat paw edema-based assay showed that the TA-NLCs hydrogel had higher inhibition of edema than the marketed corticosteroid cream.Thus, the developed TA-NLCs hydrogel showed enhanced anti-inflammatory efficacy and sustained drug permeation, suggests that the developed TA-NLCs hydrogel could be an efficacious topical delivery system for the management of AD.

MeSH

Skin, Hydrogel, Polyethylene Glycol Dimethacrylate, Triamcinolone, Hydrogels, Dermatitis, Triamcinolone Acetonide, Pharmaceutical Preparations, Drug Delivery Systems, Edema, Dermatitis, Atopic